Showcase Furniture, a prominent provider of residential furnishings, recently announced the addition of a significant ...

Iptacopan significantly slowed kidney function decline over 24 months compared with placebo in adults with IgA nephropathy. The complement inhibitor was granted accelerated approved in 2024; continued ...

Learn what happens in your body when you eat foods that support cellular health, including how nutrients protect cells, reduce inflammation, and support energy.

A research team led by the University of Bern has decoded a mechanism by which an inconspicuous succulent regulates the ...

The article, titled "Emerging roles of immune cell-derived neurotransmitters in immunity and disease," published on March 17, ...

— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — YARTEMLEA is the first and only approved ...

SEATTLE, January 27, 2026--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the first commercial shipments of YARTEMLEA ® (narsoplimab-wuug) to its distributors were completed ...

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of hematopoietic ...

(RTTNews) - Omeros Corporation (OMER) today announced that the FDA has approved YARTEMLEA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and ...

Omeros has won U.S. Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants. Omeros on Wednesday said the approval covers Yartemlea ...